← Back to Analyst Consensus 
LEGN Buy
Legend Biotech Corp
Current Price —
Implied Upside —
Analysts 22
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 4 reiterations from 4 firms
Next Earnings
Nov 10, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 13, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Oct 9, 2026 | JP Morgan | maintain | Neutral → Neutral | — | 55% |
| Oct 8, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Sep 30, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 11, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Sep 4, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 12, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Aug 12, 2026 | TD Cowen | maintain | Hold → Hold | — | 54% |
| Aug 12, 2026 | Oppenheimer | downgrade | Outperform → Perform | — | 52% |
| Aug 12, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Aug 12, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Jul 28, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Jul 27, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jul 24, 2026 | UBS | downgrade | Buy → Neutral | — | 54% |
| Jul 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jun 3, 2026 | UBS | maintain | Buy → Buy | — | 54% |
| Jun 3, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 18, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 13, 2026 | TD Cowen | maintain | Hold → Hold | — | 54% |
| May 13, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| May 13, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Apr 21, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 15, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 11, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Mar 11, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Feb 4, 2026 | Barclays | maintain | Overweight → Overweight | $80 | 53% |
| Jan 22, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $50 | 44% |
| Jan 22, 2026 | TD Cowen | downgrade | Buy → Hold | $21 | 54% |
| Jan 20, 2026 | RBC Capital | maintain | Outperform → Outperform | $66 | 55% |
| Jan 7, 2026 | Oppenheimer | initiate | — → Outperform | $75 | 52% |
| Dec 17, 2025 | Cantor Fitzgerald | maintain | Overweight → Overweight | $74 | 50% |
| Dec 12, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $50 | 54% |
| Dec 8, 2025 | UBS | maintain | Buy → Buy | $48 | 54% |
| Nov 13, 2025 | Barclays | maintain | Overweight → Overweight | $90 | 53% |
| Nov 13, 2025 | RBC Capital | maintain | Outperform → Outperform | $74 | 55% |
| Nov 13, 2025 | Cantor Fitzgerald | maintain | Overweight → Overweight | $75 | 50% |
| Oct 17, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $60 | 44% |
| Oct 9, 2025 | JP Morgan | maintain | Overweight → Overweight | $76 | 55% |
| Aug 25, 2025 | JP Morgan | maintain | Overweight → Overweight | $78 | 55% |
| Aug 12, 2025 | RBC Capital | maintain | Outperform → Outperform | $77 | 55% |
| Aug 12, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $83 | 54% |
| Jul 17, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Jul 10, 2025 | Morgan Stanley | maintain | Overweight → Overweight | $81 | 54% |
| Jul 8, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Jul 2, 2025 | UBS | maintain | Buy → Buy | $54 | 54% |
| May 14, 2025 | Truist Securities | maintain | Buy → Buy | $71 | 55% |
| May 14, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $55 | 50% |
| Apr 22, 2025 | RBC Capital | reiterate | Outperform → Outperform | $84 | 55% |
| Apr 16, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
| Apr 8, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $75 | 44% |
Price Target Trend
Jun 14, 2026 Oct 27, 2026
EPS Estimates
+1y —
0q —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days